Nonalcoholic fatty liver disease (NAFLD) is a burgeoning health problem that affects one-third of adults and an increasing number of children in developed countries. The disease begins with the aberrant accumulation of triglyceride in the liver, which in some individuals elicits an inflammatory response that can progress to cirrhosis and liver cancer. Although NAFLD is strongly associated with obesity and insulin resistance, its pathogenesis remains poorly understood, and therapeutic options are limited. Here, we discuss recent mechanistic insights into NAFLD, focusing primarily on those that have emerged from human genetic and metabolic studies.
References and Notes
Szczepaniak L. S., et al., Magnetic resonance spectroscopy to measure hepatic triglyceride content: Prevalence of hepatic steatosis in the general population. Am. J. Physiol. Endocrinol. Metab. 288, 462 (2005).
Argo C. K., Caldwell S. H., Epidemiology and natural history of non-alcoholic steatohepatitis. Clin. Liver Dis. 13, 511 (2009).
Starley B. Q., Calcagno C. J., Harrison S. A., Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 51, 1820 (2010).
Hebbard L., George J., Animal models of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 8, 35 (2011).
Romeo S., et al., Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40, 1461 (2008).
Speliotes E. K., et al., Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 7, e1001324 (2011).
Redgrave T. G., Formation of cholesteryl ester-rich particulate lipid during metabolism of chylomicrons. J. Clin. Investig. 49, 465 (1970).
Li S., Brown M. S., Goldstein J. L., Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc. Natl. Acad. Sci. U.S.A. 107, 3441 (2010).
Horton J. D., Goldstein J. L., Brown M. S., SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Investig. 109, 1125 (2002).
Uyeda K., Repa J. J., Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab. 4, 107 (2006).
Zimmermann R., et al., Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science 306, 1383 (2004).
Hooper A. J., Adams L. A., Burnett J. R., Genetic determinants of hepatic steatosis in man. J. Lipid Res. 52, 593 (2011).
Bandsma R. H., et al., Increased de novo lipogenesis and delayed conversion of large VLDL into intermediate density lipoprotein particles contribute to hyperlipidemia in glycogen storage disease type 1a. Pediatr. Res. 63, 702 (2008).
Komatsu M., et al., Citrin deficiency as a cause of chronic liver disorder mimicking non-alcoholic fatty liver disease. J. Hepatol. 49, 810 (2008).
Tanoli T., Yue P., Yablonskiy D., Schonfeld G., Fatty liver in familial hypobetalipoproteinemia: Roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity. J. Lipid Res. 45, 941 (2004).
Browning J. D., et al., Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 40, 1387 (2004).
Tappy L., Lê K. A., Metabolic effects of fructose and the worldwide increase in obesity. Physiol. Rev. 90, 23 (2010).
Donnelly K. L., et al., Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Investig. 115, 1343 (2005).
Brown M. S., Goldstein J. L., Selective versus total insulin resistance: A pathogenic paradox. Cell Metab. 7, 95 (2008).
Semple R. K., et al., Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J. Clin. Investig. 119, 315 (2009).
Bhargava R., et al., Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. Diabetes 53, 1311 (2004).
Nagle C. A., Klett E. L., Coleman R. A., Hepatic triacylglycerol accumulation and insulin resistance. J. Lipid Res. 50 (suppl.), S74 (2009).
Chakravarthy M. V., et al., “New” hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab. 1, 309 (2005).
Brown J. M., et al., CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance. J. Lipid Res. 51, 3306 (2010).
Petersen K. F., et al., Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N. Engl. J. Med. 362, 1082 (2010).
Kozlitina J., Boerwinkle E., Cohen J. C., Hobbs H. H., Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 53, 467 (2011).
Michel P. J., et al., Lack of association between an apoC3 genetic variant and liver fat content in patients with type 2 diabetes. Hepatology, published online 4 April 2011 (10.1002/hep.24334).
Petersen K. F., et al., Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc. Natl. Acad. Sci. U.S.A. 103, 18273 (2006).
Struben V. M., Hespenheide E. E., Caldwell S. H., Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am. J. Med. 108, 9 (2000).
Schwimmer J. B., et al., Heritability of nonalcoholic fatty liver disease. Gastroenterology 136, 1585 (2009).
Romeo S., Huang-Doran I., Baroni M. G., Kotronen A., Unravelling the pathogenesis of fatty liver disease: Patatin-like phospholipase domain-containing 3 protein. Curr. Opin. Lipidol. 21, 247 (2010).
Huang Y., et al., A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc. Natl. Acad. Sci. U.S.A. 107, 7892 (2010).
Welte M. A., Proteins under new management: Lipid droplets deliver. Trends Cell Biol. 17, 363 (2007).
Jenkins C. M., et al., Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J. Biol. Chem. 279, 48968 (2004).
He S., et al., A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J. Biol. Chem. 285, 6706 (2010).
Chen W., Chang B., Li L., Chan L., Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology 52, 1134 (2010).
Basantani M. K., et al., Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J. Lipid Res. 52, 318 (2011).
Yuan X., et al., Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am. J. Hum. Genet. 83, 520 (2008).
Sookoian S., et al., A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J. Lipid Res. 50, 2111 (2009).
Tian C., Stokowski R. P., Kershenobich D., Ballinger D. G., Hinds D. A., Variant in PNPLA3 is associated with alcoholic liver disease. Nat. Genet. 42, 21 (2010).
Argo C. K., Northup P. G., Al-Osaimi A. M., Caldwell S. H., Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J. Hepatol. 51, 371 (2009).
Feldstein A. E., Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin. Liver Dis. 30, 391 (2010).
Tilg H., The role of cytokines in non-alcoholic fatty liver disease. Dig. Dis. 28, 179 (2010).
Hotamisligil G. S., Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 140, 900 (2010).
Malik S. M., et al., Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transpl. 15, 1843 (2009).
Alkhouri N., Dixon L. J., Feldstein A. E., Lipotoxicity in nonalcoholic fatty liver disease: Not all lipids are created equal. Expert Rev. Gastroenterol. Hepatol. 3, 445 (2009).
Mummadi R. R., Kasturi K. S., Chennareddygari S., Sood G. K., Effect of bariatric surgery on nonalcoholic fatty liver disease: Systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 6, 1396 (2008).
Johnson N. A., George J., Fitness versus fatness: Moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology 52, 370 (2010).
Sanyal A. J., et al., Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675 (2010).
Schwimmer J. B., et al., Prevalence of fatty liver in children and adolescents. Pediatrics 118, 1388 (2006).
Fracanzani A. L., et al., Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes. Hepatology 48, 792 (2008).
Volume 332 | Issue 6037
24 June 2011
24 June 2011
Copyright © 2011, American Association for the Advancement of Science.
Published in print: 24 June 2011
Request permissions for this article.
Acknowledgments: We thank T. Rodgers for the histological sections in Fig. 1 and D. Russell, J. Goldstein, M. Brown, and J. Browning for helpful discussions. The University of Texas Southwestern Medical Center has applied to patent the association between rs738409 and NAFLD. Supported by grants from the NIH (RL1HL092550, UL1DE109584, and PO1 HL20948). H.H.H. is on the Scientific Advisory Board for Pfizer. J.D.H. is a consultant for Merck, Pfizer, and Sanofi-Aventis and is on the Scientific Advisory Board of Aegerion.
Select the format you want to export the citation of this publication.
Download this article as a PDF fileDownload PDF